Pembrolizumab plus chemotherapy as first-line therapy for advanced HER2-negative gastric or gastroesophageal junction adenocarcinoma: 4.5-year follow-up from the randomized phase III KEYNOTE-859 study

Authors:

Abstract
No abstract available
Funding Information
  • Merck

This publication has 14 references indexed in Scilit: